Therapeutic preparations of IVIg contain naturally occurring anti-HLA-E antibodies that react with HLA-Ia (HLA-A/-B/-Cw) alleles

Blood

Volumn 121, Issue 11, 2013, Pages 2013-2028

  Ravindranath, Mepur H ^a   Terasaki, Paul I ^a   Pham, Tho ^a   Jucaud, Vadim ^a   Kawakita, Satoru ^a  

^a TERASAKI FOUNDATION LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN ANTIBODY; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA CW ANTIGEN; HLA E ANTIGEN; HLA F ANTIGEN; HLA G ANTIGEN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; SEPHADEX; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; ANTIBODY; HLA C ANTIGEN; HLA-E ANTIGEN;

AFFINITY CHROMATOGRAPHY; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; BLOOD DONOR; DESENSITIZATION; FEMALE; HUMAN; IMMUNIZATION; IMMUNOASSAY; IMMUNOREACTIVITY; MALE; MICROBEAD; PARTICLE SIZE; PRIORITY JOURNAL; ADOLESCENT; ADULT; ALLELE; ANIMAL; CHEMISTRY; CROSS REACTION; EVALUATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; MOUSE;

ADOLESCENT; ADULT; ALLELES; ANIMALS; ANTIBODIES; CROSS REACTIONS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-C ANTIGENS; HUMANS; IMMUNOASSAY; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MICE; MIDDLE AGED; YOUNG ADULT;

MLCS; MLOWN;

EID: 84877631995     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-447771     Document Type: Article

References (46)

1. Negi VS, Elluru S, Sibéril S, et al. Intravenous immunoglobulin: An update on the clinical use and mechanisms of action. J Clin Immunol. 2007; 27(3):233-245.
2. Glotz D, Haymann JP, Sansonetti N, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation. 1993;56(2):335-337.
3. Tyan DB, Li VA, Czer L, et al. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation. 1994;57(4):553-562.
4. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation. 1998;66:800-805.
5. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-matchpositive recipients. Transplantation. 2000;70(6): 887-895.
6. Nair V, Sawinski D, Akalin E, et al. Effect of high-dose intravenous immunoglobulin on anti- HLA antibodies in sensitized kidney transplant candidates. Clin Transplant. 2012;26(3): E261-E268.
7. Alachkar N, Lonze BE, Zachary AA, et al. Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation. 2012;94(2):165-171.
8. Marfo K, Ling M, Bao Y, et al. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation. 2012;94(4):345-351.
9. Tongio MM, Falkenrodt A, Mitsuishi Y, et al. Natural HLA antibodies. Tissue Antigens. 1985; 26(5):271-285.
10. Luscher MA, Choy G, Embree JE, et al. Anti-HLA alloAb is found in children but does not correlate with a lack of HIV type 1 transmission from infected mothers. AIDS Res Hum Retroviruses. 1998;14(2):99-107.
11. Morales-Buenrostro LE, Terasaki PI, Marino- Vázquez LA, et al. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation. 2008;86(8): 1111-1115.
12. Zhou B, Saito S, Nakazawa Y, et al. Existence of an immunoglobulin G component of naturally occurring HLA class I antibodies that are not directed against self-antigens in human serum. Tissue Antigens. 2008;72(2):98-104.
13. Ravindranath MH, Kaneku H, El-Awar N, et al. Antibodies to HLA-E in nonalloimmunized males: Pattern of HLA-Ia reactivity of anti-HLA-E-positive sera. J Immunol. 2010;185(3):1935-1948.
14. Ravindranath MH, Taniguchi M, Chen CW, et al. HLA-E monoclonal antibodies recognize shared peptide sequences on classical HLA class Ia: Relevance to human natural HLA antibodies. Mol Immunol. 2010;47(5):1121-1131.
15. Ravindranath MH, Pham T, El-Awar N, et al. Anti-HLA-E mAb 3D12 mimics MEM-E/02 in binding to HLA-B and HLA-C alleles: Web-tools validate the immunogenic epitopes of HLA-E recognized by the antibodies. Mol Immunol. 2011; 48(4):423-430.
16. Derré L, Corvaisier M, Charreau B, et al. Expression and release of HLA-E by melanoma cells and melanocytes: Potential impact on the response of cytotoxic effector cells. J Immunol. 2006;177(5):3100-3107.
17. Coupel S, Moreau A, Hamidou M, et al. Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood. 2007;109(7):2806-2814.
18. Ravindranath MH, Selvan SR, Terasaki PI. Augmentation of anti-HLA-E antibodies with concomitant HLA-Ia reactivity in IFNg-treated autologous melanoma cell vaccine recipients. J Immunotoxicol. 2012;9(3):282-291. [Epub ahead of print]
19. Ravindranath MH, Pham T, Ozawa M, et al. Antibodies to HLA-E may account for the nondonor- specific anti-HLA class-Ia antibodies in renal and liver transplant recipients. Int Immunol. 2012;24(1):43-57.
20. Ward PA, Adams J, Faustman D, et al. Monoclonal Antibody Production A Report of the. Washington, DC: Committee on Methods of Producing Monoclonal Antibodies Institute for Laboratory Animal Research National Research Council National Academy Press; 1999:1-47
21. Sansonno DE, DeTomaso P, Papanice MA, et al. An enzyme-linked immunosorbent assay for the detection of autoantibodies to albumin. J Immunol Methods. 1986;90(1):131-136.
22. Pires ES, Parte PP, Meherji PK, et al. Naturally occurring anti-albumin antibodies are responsible for false positivity in diagnosis of autoimmune premature ovarian failure. J Histochem Cytochem. 2006;54(4):397-405.
23. Hoppe I. [Antibody screening of commercially available immunoglobulins. Erythrocyte-, HLA- and autoantibodies (author's transl)]. Blut. 1979;39(1):9-16.
24. Kaveri S, Vassilev T, Hurez V, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest. 1996;97(3):865-869.
25. Stoclin A, Delbos F, Dauriat G, et al. Transfusion-related acute lung injury after intravenous immunoglobulin treatment in a lung transplant recipient. Vox Sang. 2013;104(2): 175-178.
26. Ghio M, Contini P, Puppo F, et al. The immunomodulatory effect of blood transfusions and intravenous immunoglobulins: The role of the soluble molecules of the Class-I major histocompatibility complex and of the Fas ligand. Ann Ital Med Int. 2000;15(1):70-74.
27. Barocci S, Fenoglio D, Leprini A, et al. Anti-HLA antibodies (Ab1) and anti-idiotypic antibodies (Ab2) directed against Anti-HLA Ab1 in various preparations of polyspecific immunoglobulins for intravenous use. Boll Soc Ital Biol Sper. 1990; 66(12):1193-1200.
28. Ott VL, Fong DC, Cambier JC. Fc gamma RIIB as a potential molecular target for intravenous gamma globulin therapy. J Allergy Clin Immunol. 2001;108:(4 Suppl):S95-S98.
29. Heidt S. Roelen DL, Eijsink C, et al. Intravenous immunoglobulin preparations have no direct effect on B cell proliferation and immunoglobulin production. Clin Exp Immunol. 2009;158(1):99-105.
30. Sibéril S, de Romeuf C, Bihoreau N, et al. Selection of a human anti-RhD monoclonal antibody for therapeutic use: Impact of IgG glycosylation on activating and inhibitory Fc g R functions. Clin Immunol. 2006;118(2-3):170-179.
31. Brinc D, Lazarus AH. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. Hematology (Am Soc Hematol Educ Program). 2009;2009(1):185-191.
32. Heyman B. Regulation of antibody responses via antibodies, complement, and Fc receptors. Annu Rev Immunol. 2000;18:709-737.
33. Uhr JW, Möller G. Regulatory effect of antibody on the immune response. Adv Immunol. 1968;8: 81-127.
34. Santoso S, Kiefel V, Volz H, et al. Quantitation of soluble HLA class I antigen in human albumin and immunoglobulin preparations for intravenous use by solid-phase immunoassay. Vox Sang. 1992; 62(1):29-33.
35. Grosse-Wilde H, Blasczyk R, Westhoff U. Soluble HLA class I and class II concentrations in commercial immunoglobulin preparations. Tissue Antigens. 1992;39(2):74-77.
36. Blasczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet. 1993; 341(8848):789-790.
37. El-Awar N, Terasaki PI, Nguyen A, et al. Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol. 2009;70(10):844-853.
38. Rizk A, Gorson KC, Kenney L, et al. Transfusionrelated acute lung injury after the infusion of IVIG. Transfusion. 2001;41(2):264-268.
39. Dooren MC, Ouwehand WH, Verhoeven AJ, et al. Adult respiratory distress syndrome after experimental intravenous gamma-globulin concentrate and monocyte-reactive IgG antibodies. Lancet. 1998;352(9140):1601-1602.
40. Berger-Achituv S, Ellis MH, Curtis BR, et al. Transfusion-related acute lung injury following intravenous anti-D administration in an adolescent. Am J Hematol. 2008;83(8):676-678.
41. Voulgari PV, Paschou S, Svarna E, et al. Images in rheumatology. Transfusion-related acute lung injury during intravenous immunoglobulin treatment. J Rheumatol. 2010;37(1):190-191.
42. Gupta V, Gupta P, Yadav TP. Transfusion related acute lung injury with intravenous immunoglobulin. Indian Pediatr. 2011;48(10): 807-808.
43. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315(6): 341-347.
44. Lin YJ, Wan L, Wu JY, et al. HLA-E gene polymorphism associated with susceptibility to Kawasaki disease and formation of coronary artery aneurysms. Arthritis Rheum. 2009;60(2):604-610.
45. Allard M, Oger R, Vignard V, et al. Serum soluble HLA-E in melanoma: A new potential immunerelated marker in cancer. PLoS ONE. 2011;6(6): E21118. Epub2011Jun21.
46. Pellegrino MA, Indiveri F, Fagiolo U, et al. Immunogenicity of serum HLA antigens in allogeneic combinations. Transplantation. 1982; 33(5):530-533.